Archontoulis, Nikolaos K.Staikou, Chryssoula V.2025-12-092009-06Experimental and Clinical Transplantation, Cilt, 7, Sayı, 2, 2009 ss. 129-1321304-0855https://hdl.handle.net/11727/14082Objectives: Pneumocystis jiroveci pneumonia is common in immunocompromised individuals. Patients: This case report describes an immuno­suppressed patient who acquired P jiroveci pneumonia 6 months after renal transplant surgery. Results: The patient experienced many pneumonia-related complications and adverse effects from drug therapy, and despite treatment with various antibiotic agents, he died on the 62nd day after his admission to the intensive care unit. Conclusions: The therapeutic failure of the drug of choice (co-trimoxazole) was evident. This case raises questions about the development of P jiroveci resistance to current therapies.en-USRenal transplantImmunosuppressionAntibioticsTreatmentResistanceArticle722146-8427